Clinical trial

An Open-Label Phase I/II Study of Recombinant Granulocyte Colony Stimulating Factor (r-metHuG-CSF) and Recombinant Erythropoietin (rHuEPO) Given Subcutaneously Along With Zidovudine (AZT) to Patients With the Acquired Immune Deficiency Syndrome (AIDS) or Severe AIDS-Related Complex (ARC)

NCT00002255

Study summary

ClinicalTrials.gov

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Filgrastim Normalized identity: filgrastim View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Epoetin alfa Normalized identity: epoetin alfa View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Zidovudine Normalized identity: zidovudine View linked drug · Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start dateUnknown

PhasePHASE1

Conditions

HIV Infectionsunresolved

Interventions

FilgrastimDRUG · verified · RxNorm: filgrastim

Epoetin alfaDRUG · verified · RxNorm: epoetin alfa

ZidovudineDRUG · verified · RxNorm: zidovudine

Sponsors & collaborators

Amgenlead sponsor

Mapped research locations

Los AngelesCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00002255 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.